STOCK TITAN

Citius Oncology (CTOR) Stock Price, News & Analysis

CTOR NASDAQ

Ticker history: TENK became CTOR (Citius Oncology, Inc.) on . Earlier news and filings retain their original names and dates. View TENK history.

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
76 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+25.7% close of March 31, 2026
1-year change
-55.4% closing prices, November 20, 2025 to November 20, 2026
1-month change
-25% closing prices, October 20, 2026 to November 20, 2026

Company Description

Citius Oncology, Inc. (Nasdaq: CTOR) is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. According to the company’s public disclosures, Citius Oncology serves as a platform dedicated to bringing targeted cancer treatments to market, with an emphasis on therapies that address areas where existing options are limited.

The company is an oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR). Citius Pharmaceuticals reports that it owns a majority stake in Citius Oncology. Through this relationship, Citius Oncology concentrates on oncology assets, while its parent company advances a broader portfolio of critical care products.

Core therapy: LYMPHIR for cutaneous T-cell lymphoma

Citius Oncology’s primary asset is LYMPHIR™ (denileukin diftitox-cxdl), described in multiple company press releases as a novel IL‑2 receptor-directed fusion protein and targeted immune therapy. LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma (CTCL) after at least one prior systemic therapy. Company materials state that LYMPHIR is indicated for use in Stage I–III CTCL and is positioned as a systemic therapy option in a disease setting characterized by limited treatment choices.

According to Citius Oncology, LYMPHIR is a recombinant fusion protein that combines the IL‑2 receptor binding domain with diphtheria toxin fragments. The agent binds to IL‑2 receptors on the cell surface and, after internalization, the diphtheria toxin fragments inhibit protein synthesis, resulting in cell death. Company descriptions further note that denileukin diftitox-cxdl has demonstrated depletion of immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL‑2 receptor–expressing tumors.

Regulatory and clinical background

Company communications report that denileukin diftitox received regulatory approval in Japan in 2021 for the treatment of relapsed or refractory CTCL and peripheral T‑cell lymphoma (PTCL). In 2021, Citius obtained an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for specified territories including Japan and certain parts of Asia (and, in some disclosures, India). Citius Oncology states that LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA in August 2024 for adult patients with relapsed or refractory Stage I–III CTCL after at least one prior systemic therapy.

In company press releases describing the pivotal Study 302, Citius Oncology reports that the Phase 3 trial in Stage I–III relapsed or refractory CTCL demonstrated an objective response rate and reductions in skin tumor burden, as well as activity on severe pruritus. The company also notes that LYMPHIR was not associated with cumulative toxicity in the data it has presented.

Commercialization and market focus

Citius Oncology states that it launched LYMPHIR commercially in the United States in December 2025, transitioning from a pre‑revenue to a revenue-generating profile. The company describes LYMPHIR as its first marketed product and a key driver of its business. According to Citius Oncology and Citius Pharmaceuticals, LYMPHIR has been assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J‑code (J9161) and has been included in National Comprehensive Cancer Network (NCCN) Guidelines for CTCL with a Category 2A recommendation, which the company identifies as important elements for coverage and reimbursement.

To support U.S. access, Citius Oncology reports that it has executed service agreements with the three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations, including medical centers, specialized hospitals treating oncology patients, community oncology practices, and infusion centers. The company has also announced a distribution services agreement with McKesson Corporation, which it describes as completing its core U.S. distribution network for LYMPHIR.

Beyond the U.S., Citius Oncology describes an international access strategy based on Named Patient Programs (NPPs). Company news releases state that it has secured access to LYMPHIR in 19 markets outside the United States through regional distribution partners. These programs, as described by the company, allow access to LYMPHIR where permitted by local law but do not constitute commercial approval outside the U.S.

Intellectual property and positioning

In multiple public statements, Citius Oncology notes that LYMPHIR is supported by intellectual property protections that span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors. The company states that these protections would support its competitive positioning in the CTCL treatment landscape.

Management commentary in company press releases estimates that the initial market for LYMPHIR exceeds $400 million, is growing, and is underserved by existing therapies. This estimate is presented by the company as part of its rationale for focusing on CTCL and for viewing LYMPHIR as a value-driving asset.

Use of data and AI in commercialization

Citius Oncology has announced a collaboration with Verix to deploy the Tovana AI-powered commercial optimization platform. According to the company, this platform integrates advanced analytics, real-world claims data, and machine learning to refine commercial targeting, support real-time field execution, and enhance provider engagement for LYMPHIR. Company statements describe the goal of using AI-driven analytics to inform sales and marketing plans and to prioritize engagement with healthcare providers whose patients may be appropriate for LYMPHIR.

Corporate structure and capital markets activity

Citius Oncology is incorporated in Delaware and is identified in SEC filings as an emerging growth company. It is listed on Nasdaq under the ticker symbol CTOR. The company has reported various equity financings, including registered direct offerings and private placements, as well as the issuance and amendment of warrants. In its fiscal year 2025 financial update, Citius Oncology highlighted strategic financings intended to support the commercialization of LYMPHIR and general corporate purposes.

In SEC filings, Citius Oncology has also disclosed the adoption and subsequent amendment of its 2024 Omnibus Stock Incentive Plan, increasing the number of shares of common stock reserved for issuance under the plan. Stockholders approved this amendment at the company’s 2025 annual meeting of stockholders, as reported in a Form 8‑K.

Relationship with Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals describes itself as a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. It reports that it owns a controlling interest in Citius Oncology and that LYMPHIR is a key asset within the combined group. Citius Pharmaceuticals also discloses late-stage programs such as Mino‑Lok and CITI‑002 (Halo‑Lido), which are separate from Citius Oncology’s oncology-focused platform but provide context for the broader corporate family in which Citius Oncology operates.

Risk and regulatory considerations

Company press releases and SEC filings include extensive forward-looking statement disclosures and risk factor summaries. Citius Oncology highlights risks related to funding needs, commercialization of LYMPHIR, market acceptance, reliance on third-party logistics providers and specialty pharmacies, regulatory compliance, intellectual property, and maintaining Nasdaq listing standards, among others. These disclosures emphasize that the company’s plans and expectations are subject to uncertainties typical of emerging biopharmaceutical companies.

Stock Performance

$0.5035
-10.95%
-0.0619
Last updated: at
-55.4%
Performance 1 year
$53.2M
93.0M
Shares outstanding As of August 13, 2026.

Citius Oncology (CTOR) closed at $0.5035 on November 20, 2026. Over the past 12 months, the price has lost 55.4%.

See what a $1,000 investment in CTOR would be worth today

Average down calculator for CTOR

CTOR Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Citius Oncology has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings. View all CTOR news →

Financial Highlights

Citius Oncology reported operating income of -$23.5M in FY2025, and net income was -$24.8M. Diluted earnings per share stood at -$0.34. The company generated -$5.5M in operating cash flow. The current ratio was 0.56, measuring current assets divided by current liabilities.

-$24.8M
Net Income (FY2025)
-$5.5M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

DEC
2026
December 2026 Earnings

Q4 2026 Results

Citius Oncology will release complete quarterly and fiscal 2026 results in December 2026; webcast/timing to be announced.
Q4
2026
Q4 2026 Operations

Formulary Placement Target

Target to achieve formulary placement at 100 priority institutions by calendar year-end 2026; progress may affect LYMPHIR uptake.

Citius Oncology has 2 upcoming scheduled events. The next event, "Q4 2026 Results", is expected in December 2026. 1 of them is an earnings release or call. Investors can track these dates to stay informed about potential catalysts that may affect the CTOR stock price.

Short Interest History

Last 12 Months

Short interest in Citius Oncology (CTOR) currently stands at 201.9 thousand shares, down 11.2% from the previous reporting period, representing 0.8% of the float.

Days to Cover History

Last 12 Months

Days to cover for Citius Oncology (CTOR) currently stands at 1.2 days, down 55.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 11.4 days.

CTOR Company Profile & Sector Positioning

Citius Oncology (CTOR) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing CTOR often look at related companies in the same sector, including Zhengye Biotechnology Holding Limited (ZYBT), Cumberland Pharmaceuticals Inc (CPIX), Journey Medical Corporation (DERM), Organogenesis Holdings Inc. (ORGO), and Akebia Therapeutics, Inc. (AKBA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CTOR's relative position within its industry.

Frequently Asked Questions

The current stock price of Citius Oncology (CTOR) is $0.5035 as of November 20, 2026.

The market cap of Citius Oncology (CTOR) is approximately $53.2M. Learn more about what market capitalization means .

The FY2025 net income of Citius Oncology (CTOR) is -$24.8M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Citius Oncology (CTOR) is -$0.34 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Citius Oncology (CTOR) is -$5.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Citius Oncology (CTOR), current assets divided by current liabilities, was 0.56 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Citius Oncology (CTOR) is -$23.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

Citius Oncology, Inc. is described in its public disclosures as a platform to develop and commercialize novel targeted oncology therapies. It is the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. and trades on Nasdaq under the ticker symbol CTOR.

LYMPHIR (denileukin diftitox-cxdl) is a novel IL-2 receptor-directed fusion protein and targeted immune therapy. According to Citius Oncology, it is approved by the FDA for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Company descriptions state that LYMPHIR is a recombinant fusion protein combining the IL-2 receptor binding domain with diphtheria toxin fragments. It binds to IL-2 receptors on the cell surface, and after uptake, the toxin fragments inhibit protein synthesis, resulting in cell death. It has also demonstrated depletion of regulatory T lymphocytes and antitumor activity in IL-2 receptor–expressing tumors.

Citius Oncology reports that LYMPHIR (denileukin diftitox-cxdl) was approved by the U.S. Food and Drug Administration in August 2024 for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy.

Yes. In its fiscal year 2025 business update and related press releases, Citius Oncology states that it launched LYMPHIR commercially in the United States in December 2025, marking its transition from a pre-revenue to a revenue-generating company.

Management commentary cited in company press releases estimates that the initial market for LYMPHIR exceeds $400 million, is growing, and is underserved by existing therapies in cutaneous T-cell lymphoma.

Citius Oncology reports that it has executed service agreements with the three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations, including major medical centers, specialized hospitals, community oncology practices, and infusion centers. The company has also announced a distribution services agreement with McKesson Corporation as an authorized distributor of record.

Yes. Company news releases state that Citius Oncology has secured access to LYMPHIR in 19 international markets through regional distribution partners using Named Patient Programs. These programs provide access where permitted by local law and do not constitute commercial approval outside the United States.

Citius Oncology states that LYMPHIR benefits from intellectual property protections that include orphan drug designation, complex technology, trade secrets, and pending patents related to immuno-oncology use, including potential combination therapy with checkpoint inhibitors.

The company has announced a collaboration with Verix to use the Tovana AI-powered commercial optimization platform. According to Citius Oncology, this platform applies advanced analytics and machine learning to refine commercial targeting, support real-time field execution, and enhance provider engagement for LYMPHIR’s U.S. launch and adoption.

Citius Pharmaceuticals, Inc. describes itself as a biopharmaceutical company focused on first-in-class critical care products and reports that it owns a majority of Citius Oncology. Citius Oncology is presented as its oncology-focused subsidiary, with LYMPHIR as a key asset within the group.

Yes. In a Form 8-K and related proxy materials, Citius Oncology reported that its board approved, and stockholders later adopted, an amendment to the 2024 Omnibus Stock Incentive Plan to increase the number of shares of common stock reserved for issuance from 15,000,000 to 30,000,000 shares.